Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01518972 · ClinicalTrials.gov registry record · Phase 2
Prazosin for Alcohol Dependence and Posttraumatic Stress Disorder
A Phase 2 study, sponsored by Seattle Institute for Biomedical and Clinical Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT01518972: Completed Phase 2 study, sponsored by Seattle Institute for Biomedical and Clinical Research.
NCT01518972 is a Phase 2 study that has completed, run by Seattle Institute for Biomedical and Clinical Research. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01518972, a Phase 2 study, has completed, sponsored by Seattle Institute for Biomedical and Clinical Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the drug prazosin is effective for the treatment of alcohol dependency and symptoms of Posttraumatic Stress Disorder (PTSD).
Primary Outcome
Data for this measure came from the Form-42 and daily IVR (Interactive Voice Response) monitoring. The percentage of drinking days of each participant was calculated by summing the number of drinking days and comparing them with the number of total drinking days in the same week. The percentage of drinking days from each week was added and averaged to get the percentage of drinking days per week per participant. The percentage of drinking days of all participants in the Prazosin group was added
Interventions
- DRUG Prazosin
- DRUG Placebo medication
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2009-09 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
What the finished NCT01518972 record still lists
NCT01518972 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 2 interventions - of which Prazosin is the first listed.
NCT01518972 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01518972 about?
NCT01518972 is a clinical study titled "Prazosin for Alcohol Dependence and Posttraumatic Stress Disorder". The purpose of this study is to determine whether the drug prazosin is effective for the treatment of alcohol dependency and symptoms of Posttraumatic Stress Disorder (PTSD).
What is the current status of trial NCT01518972?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2009-09. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01518972?
The interventions under investigation include: Prazosin (DRUG), Placebo medication (DRUG).
Who is sponsoring clinical trial NCT01518972?
This trial is sponsored by Seattle Institute for Biomedical and Clinical Research, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01518972's enrollment target sits among peer trials
30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia